

Title (en)
GLUCAGON RECEPTOR ANTAGONISTS

Title (de)
GLUCAGONREZEPTORANTAGONISTEN

Title (fr)
ANTAGONISTES DU RÉCEPTEUR DU GLUCAGON

Publication
EP 3500565 A1 20190626 (EN)

Application
EP 17842024 A 20170815

Priority
• US 201662376324 P 20160817
• US 2017047031 W 20170815

Abstract (en)
[origin: WO2018035172A1] Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions and methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia.

IPC 8 full level
C07D 409/04 (2006.01); **C07D 333/24** (2006.01); **C07D 413/12** (2006.01)

CPC (source: EP US)
A61P 3/10 (2017.12 - EP US); **C07D 209/18** (2013.01 - EP US); **C07D 213/81** (2013.01 - EP US); **C07D 231/12** (2013.01 - EP US); **C07D 233/61** (2013.01 - EP US); **C07D 235/16** (2013.01 - EP US); **C07D 333/38** (2013.01 - EP US); **C07D 405/10** (2013.01 - EP US); **C07D 407/10** (2013.01 - EP US); **C07D 409/06** (2013.01 - EP US); **C07D 409/12** (2013.01 - EP US)

Citation (search report)
See references of WO 2018035172A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

DOCDB simple family (publication)
WO 2018035172 A1 20180222; EP 3500565 A1 20190626; US 2019194143 A1 20190627

DOCDB simple family (application)
US 2017047031 W 20170815; EP 17842024 A 20170815; US 201716323508 A 20170815